However, after 4 years, his cancer started progressing with speed. He and his wife discussed his case with many cancer experts. Finally, they met Dr. Akash Patnaik, a renowned national authority on prostate cancer.
By that time, Ralph's cancer had already grown significantly and reached stage 4. It had expanded to other parts of the body and became extremely difficult to control. FDA-approved traditional methods and treatments were no longer effective for him.
Immunotherapy Clinical Trial with a Promising Approach
With no standard therapies left as an option, Dr. Patnaik suggested the family consider enrolling Ralph in an immunotherapy clinical trial.This promising new approach is aimed at enabling a patient's T cells to become an efficient weapon in fighting off cancer. So, unlike chemotherapy, which can be toxic to cells that are healthy, this approach improves the immune system so the body can mount its own defense. The drugs involved in this immunotherapy are called checkpoint inhibitors.
Dr. Patnaik was leading the second phase of a clinical trial, called CheckMate 650, for prostate cancer in men. He enrolled Ralph in this clinical trial which used a combination of two drugs – ipilimumab, and nivolumab that boost the immune system.